Mesoblast (MESO) Other Operating Expenses (2015 - 2023)
Mesoblast recorded quarterly Other Operating Expenses of $972000.0 in Q2 2023, down 70.7% quarter-over-quarter from $3.3 million in Q1 2023, and up 285.5% year-over-year from $252142.6 in Q2 2022.
Mesoblast's Other Operating Expenses history runs 9 years deep, the most recent figure standing at $972000.0 for Q2 2023.
- In Q2 2023, Other Operating Expenses rose 285.5% year-over-year to $972000.0; the TTM figure through Dec 2024 stood at $972000.0 (down 78.59% YoY), while the FY2025 annual figure was $3.1 million, up 18.79% from the prior year.
- Other Operating Expenses came in at $972000.0 for Q2 2023 at Mesoblast, down from $3.3 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $3.3 million in Q1 2023 to a low of -$524000.0 in Q2 2022.
- A 5-year average of $270833.3 and a median of $120000.0 in 2020 frame the typical range for Other Operating Expenses.
- Across the five-year window, Other Operating Expenses jumped 1603.85% in 2020 and slumped 471.63% in 2022, its largest moves.
- Mesoblast's Other Operating Expenses stood at $143000.0 in 2019, then surged by 106.99% to $296000.0 in 2020, then slumped by 176.69% to -$227000.0 in 2021, then jumped by 210.57% to $251000.0 in 2022, then soared by 287.25% to $972000.0 in 2023.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $972000.0, $3.3 million, and $251000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 972,000.00 |
| Mar 31, 2023 | 3.32 Mn |
| Dec 31, 2022 | 251,000.00 |
| Sep 30, 2022 | -504,000.00 |
| Jun 30, 2022 | -524,000.00 |
| Mar 31, 2022 | 392,000.00 |
| Dec 31, 2021 | -227,000.00 |
| Sep 30, 2021 | -178,000.00 |
| Jun 30, 2021 | 141,000.00 |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 296,000.00 |
| Sep 30, 2020 | 99,000.00 |
| Jun 30, 2020 | 391,000.00 |
| Mar 31, 2020 | -442,000.00 |
| Dec 31, 2019 | 143,000.00 |
| Sep 30, 2019 | -169,000.00 |
| Jun 30, 2019 | -26,000.00 |
| Mar 31, 2019 | -82,000.00 |
| Dec 31, 2018 | -827,000.00 |
| Sep 30, 2018 | -151,000.00 |
| Jun 30, 2018 | 69,000.00 |
| Mar 31, 2018 | 152,000.00 |
| Dec 31, 2017 | 423,000.00 |
| Sep 30, 2017 | 668,000.00 |
| Jun 30, 2017 | 321,000.00 |
| Mar 31, 2017 | 384,000.00 |
| Dec 31, 2016 | 311,000.00 |
| Sep 30, 2016 | 473,000.00 |
| Jun 30, 2016 | -177,000.00 |
| Mar 31, 2016 | 547,000.00 |
| Dec 31, 2015 | 1.50 Mn |